Koyama K, Akiyama K, Kawahara H, Egashira A, Murakami H
Technical Research Center, Marubeni Feed Co., Hyogo.
Jpn J Cancer Res. 1990 Oct;81(10):967-70. doi: 10.1111/j.1349-7006.1990.tb03332.x.
Alloimmunization with the cultured human stomach cancer cell lines MKN-45 and MKN-28 was conducted and human-human hybridomas were established. Living MKN-45 cells (10(7) cells per injection) were injected monthly 34 times into one of the authors (K.K.) over 2 years and living MKN-28 cells (10(7) cells per injection) were co-injected 14 times after the 20th injection of MKN-45 alone. Cultured stomach cancer cells injected subcutaneously into K.K.'s forearm were rejected completely, although they grew transiently at the injection site. All the injections were made voluntarily at the direction of K.K. himself. Two human-human hybridomas producing monoclonal antibodies reactive with MKN-45 and MKN-28 cells, respectively, were separated from a hybridoma of human B-lymphoblastoid cell line named HO 323/WIL2-NS and lymphocytes in K.K.'s peripheral blood. One cell line of the hybridoma FMK-H3 produced IgM-type monoclonal antibody, and the other line, EMK-F7, produced IgG-type antibody. These two human-human monoclonal antibodies were highly reactive with MKN-45 and MKN-28 cells, weakly reactive with MKN-74 stomach cancer cell line, and not reactive with the other stomach cancer cell lines tested (MKN-1, MKN-7, TMK-1, NUGU-2, NUGC-3, NUGC-4 and KATO-III).
用培养的人胃癌细胞系MKN - 45和MKN - 28进行同种免疫，并建立了人 - 人杂交瘤。在两年内，将活的MKN - 45细胞（每次注射10⁷个细胞）每月注射1次，共34次，注射给其中一位作者（K.K.）；在单独注射MKN - 45细胞20次后，将活的MKN - 28细胞（每次注射10⁷个细胞）共注射14次。皮下注射到K.K.前臂的培养胃癌细胞虽然在注射部位短暂生长，但最终被完全排斥。所有注射均由K.K.本人自愿按照自己的指示进行。从名为HO 323/WIL2 - NS的人B淋巴母细胞系杂交瘤和K.K.外周血淋巴细胞中分离出两种分别产生与MKN - 45和MKN - 28细胞反应的单克隆抗体的人 - 人杂交瘤。杂交瘤FMK - H3的一个细胞系产生IgM型单克隆抗体，另一个细胞系EMK - F7产生IgG型抗体。这两种人 - 人单克隆抗体与MKN - 45和MKN - 28细胞高度反应，与MKN - 74胃癌细胞系弱反应，与其他测试的胃癌细胞系（MKN - 1、MKN - 7、TMK - 1、NUGU - 2、NUGC - 3、NUGC - 4和KATO - III）无反应。
